Anti-ARID1A monoclonal antibody, clone FQS24612 Knockout Validated

Endometrial cancers (EC) can be assigned to two groups that differ in epidemiology, clinical course, and prognosis. Type I EC is diagnosed in 80% of all patients with EC, the majority of whom suffer from metabolic syndrome. Type I EC manifests a slow course with a favorable prognosis and demonstrates hormonal receptors for estrogens and progesterone, mutations in the suppressor PTEN gene and the PI3K/Akt signaling pathway, K-ras, beta-catenin, MMR, and in ARID1A. The more aggressive, though less common Type II EC, is associated with several histological types: serous, light cell, and low differentiated carcinomas. Mutations occur in p53, HER2/neu, E-cadherin, and in ER alpha, which has a poor prognosis. In 2013, four groups of EC were distinguished on the basis of molecular alterations. Studies continue on associating histopathological and molecular alterations in various types of cancer to distinguish the group with the poorest outcome in order to precisely determine prognosis in EC.

Epidemiologic and histopathologic associations between endometriosis and epithelial ovarian cancer have been reported; however, the underlying molecular and cellular mechanisms are not well understood. A possible genetic link has been suggested in recent publications. Driver mutations in PIK3CA, KRAS, ARID1A, and other genes have been found in the epithelium of intrauterine endometrial tissue, ovarian and extraovarian pelvic endometriosis tissue, ovarian cancers associated with endometriosis (i.e., clear cell and endometrioid type), and other epithelial ovarian cancers. This makes sense because pelvic endometriosis occurs primarily as a result of retrograde menstruation and implantation of endometrial tissue fragments in ovarian inclusion cysts or extraovarian peritoneal or subperitoneal sites. Unlike epithelial cells, endometriotic stromal cells are mutation free but contain widespread epigenetic defects that alter gene expression and induce a progesterone-resistant and intensely inflammatory environment, driven by estrogen via estrogen receptor-beta. The resulting increased estrogenic action in the stroma drives inflammation and sends paracrine signals to neighboring epithelial cells to enhance proliferation. In addition, massively high concentrations of estrogen in the ovary may exert an additional and direct genotoxic effect on DNA and cause accumulation of additional mutations and malignant transformation in initially mutated endometriotic epithelial cells in an ovarian endometrioma, which may initiate epithelial ovarian cancer. The same epithelial mutations and inflammatory processes in stroma are seen in extraovarian deep-infiltrating endometriosis, but carcinogenesis does not occur. We provide a focused review of the literature and discuss the implications of recent genetic break-throughs linking endometriosis and ovarian cancer.